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Abstract
Purpose of Review Cancer diagnosis in young pregnant women challenges oncological decision-making. The International
Network on Cancer, Infertility and Pregnancy (INCIP) aims to build on clinical recommendations based on worldwide collab-
orative research.
Recent Findings A pregnancy may complicate diagnostic and therapeutic oncological options, as the unborn child must be
protected from potentially hazardous exposures. Pregnant patients should asmuch as possible be treated as non-pregnant patients,
in order to preserve maternal prognosis. Some approaches need adaptations when compared with standard treatment for fetal
reasons. Depending on the gestational age, surgery, radiotherapy, and chemotherapy are possible during pregnancy. A multidis-
ciplinary approach is the best guarantee for experience-driven decisions. A setting with a high-risk obstetrical unit is strongly
advised to safeguard fetal growth and health. Research wise, the INCIP invests in clinical follow-up of children, as cardiac
function, neurodevelopment, cancer occurrence, and fertility theoretically may be affected. Furthermore, parental psychological
coping strategies, (epi)genetic alterations, and pathophysiological placental changes secondary to cancer (treatment) are topics of
ongoing research.
Summary Further international research is needed to provide patients diagnosed with cancer during pregnancy with the best
individualized management plan to optimize obstetrical and oncological care.
Keywords Cancer . Pregnancy . Research . Fertility . INCIP
Introduction
The rarity of cancer in pregnancy complicates patient counsel-
ling and decision-making. Historically, most evidence is
derived from retrospective, observational data as ethical con-
siderations limit randomized studies. In 2005, encouraged by
a young pregnant patient with cervical cancer who was des-
perate to keep her pregnancy, a medical team from the
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University Hospitals of Leuven launched a taskforce “Cancer
in Pregnancy,” under the umbrella of the European Society of
Gynaecological Oncology (ESGO). The lack of knowledge
inspired the team to start a unique registry that combines both
oncological and obstetric data of women with a cancer diag-
nosis during pregnancy. Over the years, more differentiated
studies in this topic were initiated, and the research group
expanded and gained more international interest. As fertility
preservation became a point of interest, the research was ex-
tended with “fertility in young women with cancer.” In 2014,
the taskforce was transformed to the “International Network
of Cancer, Infertility and Pregnancy” (INCIP), still supported
by ESGO (www.cancerinpregnancy.org). Nowadays this
network consists of 67 participating hospitals from 28
countries, which are all compliant with the INCIP study
protocol. Meetings are organized to brainstorm on new
research topics and discuss ongoing research.
The epidemiology of a cancer diagnosis during pregnancy
is difficult to study as nationwide registries do not usually
combine both obstetrical and oncological data, resulting in a
likely underestimation of the incidence of cancer-related mis-
carriages or abortions. Also, population-based studies differ in
inclusion criteria, often incorporating postnatal cancer diagno-
ses. Hence, studies focusing solely on cancer during pregnan-
cy report incidence rates of 17 per 100,000 live births and 25–
27 per 100,000 pregnancies [1–3].With the increasing trend to
postpone childbirth to a later age, the incidence is expected to
increase. The introduction of the non-invasive prenatal (NIP)
test to detect major fetal chromosomal abnormalities in obstet-
rical care results in a further increase of cancer detection (in
asymptomatic pregnant patients) [4, 5].
In general, oncological treatment during pregnancy is fa-
vored over termination of pregnancy, which has not been
shown to improve prognosis, and over elective preterm deliv-
ery with its impact on neonatal health [6–8]. Preterm birth,
rather than chemotherapy exposure, was found to have an
impact on neonatal neurodevelopment [9–11]. Treatment
should adhere to protocols presented to non-pregnant women
matched for age, offering pregnant women similar prognoses
to non-pregnant age-matched women [7, 12, 13].
Chemotherapy can be used during the 2nd and 3rd trimesters
until 35 weeks of gestation, with a 3-week therapy-free inter-
val prior to delivery.
The initial aim of the INCIP registry was to provide evi-
dence on obstetric and oncological outcomes of patients with
cancer in pregnancy. The most important conclusion of the
interim analysis on 1170 patients was that over the past
20 years more patients initiated oncological treatment during
pregnancy, resulting in more live births and less preterm births
[10••]. Currently, 2059 patients with a cancer diagnosis or
oncological treatment during pregnancy, 395 young women
with cancer that received fertility preservation, and 199 pa-
tients with a cancer diagnosis within 2 years after delivery are
registered by the INCIP (Fig. 1). Most patients are registered
in Belgium, the Netherlands, Italy, and the USA and one-third
of participating centers are non-European. Breast cancer
(40%), lymphoma (12%), and cervical cancer (10%) are the
most frequent registered cancer types during pregnancy. The
majority of patients (67%) received antenatal cancer treatment
consisting of surgery (28%), chemotherapy (40%), radiation
therapy (1%), targeted therapy (2%), or a combination (28%).
Most pregnancies (88%) ended in a live birth, albeit 47%
delivered preterm, of which one-third delivered before
34weeks of gestation. One-fifth of neonates (21%) were small
for gestational age (SGA). Congenital malformations were
reported in 3% of the live births, which is comparable to the
expected rate in the general population.
Current and future collaborations within the INCIP net-
work will provide data that are sufficiently large to formulate
recommendations based on solid evidence in order to support
physicians and their patients in the challenging clinical deci-
sion-making. Here, we discuss current evidence on the most
common cancers diagnosed during pregnancy, based on con-
sensus meetings initiated by the INCIP, as well as the future
research goals of the INCIP.
Current Evidence on Management of Cancer
in Pregnancy
Breast Cancer
Pregnancy-induced physiological changes challenge the diag-
nosis of breast cancer and might delay diagnosis. Hence,
women face a 2.5-fold higher risk of being diagnosed at
higher stages of disease with inferior oncological prognosis
[6]. Approaches to diagnosis differ slightly in that ultrasound
is first line during pregnancy rather than proceeding directly to
mammography when a patient presents with a palpable mass.
Once ultrasound detects a suspicious solid mass, biopsy is
performed. Mammography can be performed during pregnan-
cy with a low fetal exposure risk to detect contralateral or
multifocal disease, despite limitations of increased parenchy-
mal density found in pregnancy. Gadolinium-enhanced mag-
netic resonance imaging (MRI) is superior to unenhanced in
the evaluation of breast cancers; however, as gadolinium is
known to cross the placenta, it is not recommended to perform
an enhanced breast MRI during pregnancy [14]. While
diffusion-weighted whole-body MRI is a superior alternative
to conventional imaging for staging, the diagnostic utility of
diffusion-weighted MRI of the breast (without contrast) is still
under investigation [15, 16]. Also pineapple juice has been
introduced as an alternative contrast agent for diffusion-
weighted whole-body MRI without known negative impact
on fetal health [17]. Lactating patients can safely continue
breastfeeding after gadolinium-enhanced MRI. Review of
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the literature shows no evidence to suggest that oral ingestion
by an infant of the small amount of gadolinium excreted into
breast milk would cause toxic effects [18–20].
Sentinel lymph node (SLN) biopsy can be considered
during pregnancy instead of standard axillary lymph
node dissection for early stage, clinically node-negative
breast cancer. Han et al. reported that SLN biopsy dur-
ing pregnancy had a comparable low axillary recurrence
rate as in non-pregnant women and appeared safe for
mother and unborn child [11]. The preferred technique
is a 1-day protocol using lower doses of 99mTc-labeled
albumin nanocolloid without lymphazurin blue dye,
which carries a risk for anaphylaxis.
Loibl et al. summarized recent advances in the care of
pregnant women with breast cancer [12]. Surgical approach
and options remain identical to standards for non-pregnant
patients. Radiotherapy is frequently delayed until postpar-
tum, using chemotherapy during the interval between lump-
ectomy and delivery. Where needed, radiotherapy during
early pregnancy can be considered. Chemotherapy should
include anthracyclines (doxorubicin or epirubicin) with cy-
clophosphamide and paclitaxel in sequential sequence, sim-
ilar to non-pregnant women. Chemotherapy can be started
from the 2nd trimester of pregnancy onwards, when organ-
ogenesis is completed, until 35 weeks of gestation, with a 3-
week therapy-free interval prior to delivery [9, 21].
Trastuzumab, found to affect fetal renal development when
used in the 2nd and 3rd trimesters of pregnancy leading to
reversible oligohydramnios, is not recommended during
pregnancy [22]. Inadvertent exposure in women who con-
ceive while taking trastuzumab does not necessarily require
termination of pregnancy since transplacental transfer of IgG
molecules only starts after this gestational period [22].
Trastuzumab does not induce congenital malformations
though the associated absence of amniotic fluid results in
fetal asphyxia and death. Therefore, a single exposure of
trastuzumab that does not lead to anhydramnion is not an
indication for interruption of pregnancy.
Women with pregnancy-related breast cancer appear to
have a similar survival as non-pregnant stage-matched breast
cancer patients. Amant et al. showed a similar overall survival
(OS) of women with pregnancy-related breast cancer (n =
311) and non-pregnant controls (n = 865) [23]. In a large
Norwegian cohort (n = 42,511), no statistically significant dif-
ference was observed in cause-specific death between preg-
nant and non-pregnant breast cancer patients (hazard ratio
1.23, 95% confidence interval (CI) 0.83 to 1.81) [3].
Gynecological Cancers
The most common gynecological cancers diagnosed during
pregnancy are cervical and ovarian cancers, whereas vulvar,
vaginal, and endometrial cancers are very rare. Due to the
proximity of the tumor to the developing fetus, diagnostic
and therapeutic strategies might need to be modified.
Cervical cancer is often diagnosed at an early stage during
pregnancy, usually around the 18th week of pregnancy [24•].
The prognosis of the disease seems not to be influenced by the
pregnancy itself [24•]. Preoperative evaluation consists of col-
poscopy, expert ultrasonography, and MRI without gadolinium
contrast agent. Computed tomography (CT) and positron emis-
sion tomography (PET) should be avoided, although low-dose
CT and PET may be considered when results potentially change
management or alternative diagnostics are inconclusive.
In early-stage tumors, a pelvic lymphadenectomy is a stan-
dard staging procedure, which is feasible during pregnancy
until the 22nd week. The choice of laparoscopic or
laparotomic approach is based on local expertise; however
laparoscopy, if performed in less than 90 min, was found to
cause less complications and preterm contractions [25].
Regarding the surgical procedure on the cervix, a simple
trachelectomy is preferred to a radical trachelectomy, which
has a high rate of obstetrical and surgical complications [26•].
At a more advanced gestational age or in higher stages of
disease (IB3, FIGO 2018), neo-adjuvant chemotherapy is the
only pregnancy-sparing therapeutic procedure. Neo-adjuvant
Fig. 1 Overview of current registered cases in the INCIP registry (August 2019, n = 2653)
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platinum-based chemotherapy in non-pregnant patients is
gaining more attention nowadays [27]. Three-weekly combi-
nation of platinum and paclitaxel or a dose-dense combination
of platinum with ifosfamide or anthracycline could be used
[26•]. When opting for non-pregnancy-sparing management,
a radical hysterectomywith the fetus in utero (during the 1st or
early 2nd trimester) or after hysterotomy (during the late 2nd
trimester) can be performed. Chemoradiation with the fetus in
utero can be applied when diagnosed during the 1st trimester
(resulting in fetal loss within a few days) while hysterotomy
and evacuation of the uterus as a first step is advised when
diagnosed during the 2nd trimester [26•]. When cervical can-
cer is still in situ, a cesarean section is mandatory in order to
avoid implants in the episiotomy site. A corporeal incision is
advised in order to avoid abdominal wound implants.
Adnexal masses are found in approximately 2–4% of the
pregnancies [28]. Ultrasonography is the main diagnostic tool,
while tumor markers are less valuable due to gestational
changes. Surgical staging, including infracolic omentectomy,
appendectomy, pelvic-peritoneal biopsies, lymph node dissec-
tion, and frozen section examination if indicated, is ideally
performed between the 14th and 22nd weeks. Restaging post-
partum should be organized if the Douglas pouch could not be
reliably examined. In the case of advanced epithelial tumors,
chemotherapy is administered in a neo-adjuvant setting since
cytoreduction to no residual tumor is not feasible during preg-
nancy. During pregnancy, a higher frequency of non-epithelial
tumors is being found due to the younger age of patients.
These cases could often be treated by pregnancy-preserving
procedures.
Only a few cases of vulvar cancer have been reported,
usually diagnosed at an early stage. Standard treatment con-
sists of radical local excision with a dissection of unilateral or
bilateral lymph node dissection. If indicated, a SLN biopsy
using technetium in a short-term protocol or indocyanine
green can be performed in pregnancy [26•].
Hematological Cancers
Lymphomas are more commonly diagnosed during pregnancy
than leukemia, with an estimated incidence of one in 6000 and
one in 75,000–100,000 pregnancies respectively [29]. As in
general, Hodgkin and non-Hodgkin lymphomas should be
treated as in non-pregnant patients [30•]. Depending on ma-
ternal symptoms, cancer stage, and aggressiveness of the he-
matological entity, immediate cytotoxic treatment, or a defer-
ral of treatment until after delivery in well-selected cases, can
be considered. Chemotherapeutic agents, especially when ad-
ministered in combination, should be avoided during the 1st
trimester. Commonly used regimens for lymphomas (doxoru-
bicin, bleomycin, vincristine, dacarbazine (ABVD) or cyclo-
phosphamide, hydroxydaunorubicin, oncovin, prednisone
(CHOP)) can be considered from the 2nd trimester of
pregnancy with regular obstetrical follow-up to safeguard fetal
growth [29, 31•]. Aviles et al. reported on reassuring outcome
of 54 newborn babies prenatally exposed to chemotherapy for
hematological malignancies during the 1st trimester of preg-
nancy [32]. Data of this series can be useful in counselling
patients who were accidentally exposed to cytotoxic drugs in
pregnancy. However, early pregnancy is a very vulnerable
period as fetal organogenesis takes place and chemotherapy
during the 1st trimester of pregnancy should be avoided if
maternal condition allows, until more safety data are available.
There is some experience with rituximab, an anti-CD20
monoclonal antibody, that is commonly used for the treatment
of non-Hodgkin lymphoma and its use might be considered
from the 2nd trimester onwards [33]. In a large retrospective
observational study, progression-free and overall survival for
77 patients with HL during pregnancy was not significantly
different from 211 non-pregnant patients matched for stage
and prognostic scores [31•].
Leukemia in pregnancy presents a very difficult challenge
and initiation of treatment should not be delayed in order to
avoid any impact on maternal prognosis. In early pregnancy,
termination is often unavoidable to conserve maternal prog-
nosis, given the teratogenicity of antineoplastic agents, and the
potential for maternal complications during periods of ex-
treme pancytopenia and immunosuppression. In these cases,
induction chemotherapy prior to termination of pregnancy
sometimes needs to be considered in order to allow a safe
termination. Leukapheresis can be considered during pregnan-
cy and is indicated in the presence of significant leukocytosis-
and leukostasis-related complications, such as vascular occlu-
sion. Thromboprophylaxis should be considered especially in
pregnant patients with leukemia as the hypercoagulable state
of pregnancy can be aggravated by myeloproliferative
neoplasms.
Current Evidence on Pharmacokinetics
Physiological gestational changes can influence all pharmaco-
kinetic parameters. A significant increase in plasma volume,
extracellular water, and body fat can change the distribution
volume [34]. Additionally, a decrease in plasma protein con-
centrations, an increased glomerular filtration and changes in
hepatic metabolizing enzyme activity have been reported in
pregnancy. This gestational effect is expected to be most pro-
nounced in the 3rd trimester of pregnancy. These altered phar-
macokinetics potentially have an effect on both the efficacy
and safety of drug treatment.
Data on pharmacokinetics of chemotherapy during preg-
nancy are scarce and current evidence is based on relatively
small case series. Compared with non-pregnant patients, a
decreased area under the curve (AUC), decreased peak plasma
concentration, and an increased distribution volume have been
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reported (epirubicin, doxorubicin, docetaxel, and paclitaxel)
[35, 36]. This effect appears to be more apparent for taxanes
than for anthracyclines. Yet, there is no evidence of inferior
survival of patients with a cancer diagnosis or treatment dur-
ing pregnancy [3, 23, 31•]. Thus, current recommendations
advice to prescribe chemotherapy based on the actual body
weight of pregnant women and do not support gestation-
related dose adaptations of cytotoxic drugs [12, 26•, 35].
Current Evidence on Outcome of Children
and Ongoing Research
An increased awareness of the feasibility of cancer treatment
during pregnancy resulted in more pregnant women receiving
antenatal treatment and more live births [10••]. Indeed, chemo-
therapy administered after the 1st trimester of pregnancy does
not cause fetal malformations, but it might increase the risk of
neonatal complications [8, 10••]. Prematurity is the most com-
mon adverse outcome reported. It represents the main determi-
nant for early postnatal complications as well as impaired
neurodevelopmental outcome, with the most immature infants
bearing the highest risk [8, 37–42]. Early neonatal complica-
tions include neonatal death, neonatal intensive care unit
(NICU) admission, SGA, hematologic disturbances, and
prematurity-related disorders (respiratory distress syndrome,
metabolic disturbances, sepsis, jaundice, and necrotizing en-
terocolitis) [10••, 11••, 12, 13, 38, 43–45]. In the cancer in
pregnancy population, preterm birth is likely to be medically
induced for maternal oncological reasons. However, during the
last two decades, a reduction of iatrogenic preterm deliveries
(relative risk (RR) 0.91, IC 0.84–0.98) has been reported [10••].
Although evidence is still controversial, SGA seems to be
more common after cancer in pregnancy, especially when
chemotherapy is administered during pregnancy. An increas-
ing incidence of SGA in chemotherapy-exposed newborns
has been reported, which might expose the infants to an in-
creased risk of perinatal mortality and morbidity [8, 10••, 32,
37, 40, 42, 43]. Interestingly, few data are available on the real
incidence of intrauterine growth restriction (IUGR). Yet,
IUGR infants carry the highest risk for short- and long-term
complications. Initiating chemotherapy before 15 weeks of
gestation appears to significantly increase the risk for IUGR
(OR 3.0) [46]. But treatment delay for fetal protection should
always be balanced against the maternal risk of postponing
chemotherapy. Other factors, such as maternal stress, the nu-
tritional state, and the disease itself, may contribute to the
observed effect. This observation highlights the need of care-
ful biometric and umbilical and brain Doppler surveillance,
especially during and after chemotherapy administration.
Transient hematotoxicity is a potentially serious, although
rare, neonatal side effect of chemotherapy administered to the
mother [43]; therefore, a 3-week window between the last
cycle of chemotherapy and delivery is suggested to allow fetal
bone marrow recovery. A recent study investigated the inci-
dence of neonatal leukopenia (white blood cells < 5000/mm3;
3%) and neutropenia (neutrophils < 1000 mm3; 7%) after che-
motherapy exposure; neutropenia was more common when
chemotherapy was given 22 to 28 days before birth, while
the risk of leukopenia was highest if delivery occurred less
than 7 days from chemotherapy [21].
Among long-term complications, neurodevelopmental im-
pairment, cardiotoxicity, ototoxicity, endocrine disorders, and
secondary malignancy have been reported. Concerns still exist
on the potential detrimental effects of maternal cancer treat-
ment on the fetal brain and subsequent neurocognitive impair-
ments. The developing brain remains vulnerable throughout
the whole pregnancy, especially during the last trimester in
which multiple crucial biological processes occur. No congen-
ital brain malformations or acquired brain lesions were ob-
served and no significant differences were found in both re-
gional and total brain volumes of infants prenatally exposed to
chemotherapy (n = 21; 81% epirubicin) compared with con-
trol infants matched for gestation at birth [47].
Reassuring neurocognitive outcomes have been reported in
children born to mothers with cancer, mainly by retrospective
cohort studies [32, 42, 48, 49]. In 2015, Amant et al. reported
no effect of cancer treatment on neurobehavioral performances at
36 months, although an independent effect of prematurity on
cognitive outcome was demonstrated [8]. Longer follow-up data
on cognitive, behavioral, and academic performances are neces-
sary considering the known “chemo-brain” effect. Impairment in
attention and executive functions has been described in child-
hood cancer survivors treated with chemotherapy [50].
According to specific drug exposure, surveillance on long-
term cardiotoxicity (after anthracyclines exposure) and hearing
impairment (cisplatin) is recommended. However, the evidence
regarding cardiac function on children prenatally exposed to
anthracyclines is reassuring: non-clinically relevant differences
in echocardiographic findings have been reported in exposed
children compared with non-exposed ones [8, 42, 51, 52].
Concerns related to hearing function throughout infancy are
mainly based on data from young cancer survivors [53, 54].
However, on indication, the use of carboplatinum during preg-
nancy is preferred, as there are case reports of impaired hearing in
children prenatally exposed to cisplatin [8, 41, 55]. The occur-
rence of endocrine disturbances as well as secondarymalignancy
needs to be investigated in long-term cohort studies.
Current Evidence on Psychological Coping
Strategies and Ongoing Research
When future parents are confronted with a cancer diagnosis
during pregnancy, they will experience a rollercoaster of am-
biguous emotions; the joy of being pregnant and motherhood
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might become overwhelmed by fear for the lives of the mother
and unborn child. In a retrospective study, 21–52% (based on
two self-administered psychological questionnaires) of 74
pregnant women with a cancer diagnosis self-reported signif-
icant levels of distress, which is higher than published rates in
healthy pregnant women (15%) and breast cancer patients
(20–40%) [56–58]. The INCIP retrospectively investigated
different coping strategies for patients and their partners by
questionnaires (Cognitive Emotion Regulation Questionnaire
(CERQ)) and a newly constructed Cancer and Pregnancy
questionnaire [59]. One might use three different coping strat-
egies: positive coping, internalizing coping, and blaming.
Couples using internalizing coping strategies deal with the
highest levels of distress and may benefit from additional psy-
chosocial support. Ongoing research aims to validate the
Cancer and Pregnancy questionnaire, in order to implement
it in clinical practice as a tool for healthcare workers to provide
patient-oriented psychological support.
Current Evidence on Placental Aspects
and Ongoing Research
The risk of SGA in cancer in pregnancy is two- to threefold
higher than that in the general population, especially after
administration of platinum-based agents [10••]. Deficient pla-
cental nutrient and oxygen supply account for up to 90% of all
SGA pregnancies in the general population [60, 61]. Maternal
cytotoxic treatment penetrates the placenta and subsequently
might affect placental development and fetal growth. Only a
limited number of (mainly animal) studies have been focusing
on placental changes due to maternal cancer (treatment). The
placental weight of untreated tumor-bearing animals is signif-
icantly reduced in comparison with non-tumor-bearing con-
trols and morphologic differences have been observed [62,
63]. Also an increased level of oxidative stress and an affected
DNA repair system in placental tissue have been noticed [62,
64]. To date, only two studies have been evaluating
chemotherapy-related placental changes in women. The first
showing non-specific placental findings including villous hy-
poplasia (n = 13) and the second confirming enhanced oxida-
tive damage (n = 25) [65, 66]. Genetic changes have been only
studied after exposure to alkylating agents in non-tumor-
bearing animal models, confirming dose-dependent DNA ad-
duct levels in placental tissue and methylation of placental
DNA, endorsing the oncogenic character of these drugs [67,
68]. Placental irradiation effects have only been studied in one
mice study, showing no morphological changes, but reduced
placental weights and significantly altered expression of genes
related to oxidative damage [69].
Placental metastases are mainly reported in women with
malignant melanoma (22–50%) and are assumed to be
hematogenously disseminated [70–74]. They typically occur
in women with otherwise metastatic disease [72]. Due to a
suggested placental barrier between the maternal and fetal
interface, placental metastases are mainly located in the
intervillous space and to a lesser extent in the villi [75]. Fetal
involvement is rare and always preceded by villous invasion
of maternal cancer cells [75]. Histopathological placental ex-
amination is crucial in identifying potential fetal involvement
and should be strongly considered in women with a cancer
diagnosis, especially in a metastasized setting. Limited knowl-
edge about placental changes has led to the implementation of
the placenta study in order to study cancer (treatment) effects.
Placental (epi)genetic changes and subsequent long-term risks
to these infants are subject of ongoing studies. Also, studies on
meconium of infants, who were prenatally exposed to an ex-
panded panel of chemotherapeutic agents and metabolites,
after a successful detection of paclitaxel and metabolites, fur-
ther explore direct fetal exposure [76].
Importance of a Multidisciplinary Advisory
Board and Development of a Clinical Pathway
for Cancer and Pregnancy
Even though the co-incidence of cancer and pregnancy is
slowly increasing, it is still a rare event. The consequence is
that individual doctors see less than one pregnant patient with
cancer a year. Adding the heterogenic character of the popu-
lation with all the different types of cancer occurring at differ-
ent gestational ages, an experienced multidisciplinary team is
indispensable in order to provide optimal care for both mother
and child. This team should at least include a medical oncol-
ogist, perinatologist, gynecologic oncologist, pediatrician, ra-
diotherapist, and psychologist or social worker. Other valu-
able members are a geneticist and clinical pharmacologist.
Depending on the type of cancer, a surgeon, hematologist, or
other specialists should be added (Fig. 2).
As defined by the European Reference Networks (ERNs)
for rare diseases, a disease is considered rare if the number
of affected people is less than 1 in 2000 [77]. This implies
that cancer in pregnancy qualifies as a rare disease. The care
for patients with a rare disease is complicated by the small
number of patients, lack of evidence-based diagnostic and
treatment options, logistic problems due to the scattering of
patients across countries, and limited clinical expertise. It is
widely accepted that increased exposure of a medical spe-
cialist to a rare health problem improves knowledge and
quality of care [78].
With the expanding number of experienced healthcare
professionals, the INCIP could theoretically act as an
ERN that connects healthcare professionals in Europe.
Representatives of the ERN would collect their expertise
into national advisory boards.
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In the Netherlands, a first step in realizing a reference net-
work has been made in 2012, when the national “Advisory
Board on Cancer in Pregnancy” was established. This adviso-
ry board consists of healthcare professionals from different
hospitals and covers most of the specialisms involved in the
care of pregnant cancer patients. All involved professionals
have their own expertise and are available for consultation
by other healthcare professionals confronted with a pregnant
patient with cancer. The aim is to advise healthcare profes-
sionals on optimal care, based on up-to-date information about
the possibilities and risks of diagnostics and treatment. The
board will advise referral to another hospital if specific exper-
tise is required and aims to include these patients into the
ongoing INCIP research projects.
International advisory boards on specific malignancies
would require digital support with easy access to all available
recommendations and links to research projects, specialized
national referral hospitals, and patient information. Consensus
meetings can aid the establishment of up-to-date and
experience-based guidelines. Finally, (inter)national boards
can facilitate an e-learning or interactive online course to in-
crease knowledge and awareness on cancer in pregnancy,
leading to improved care and possible improved outcome.
Conclusion
With the establishment of INCIP, a crucial step has been made
in the improvement of care for pregnant cancer patients and
their offspring. Most of the current knowledge is based on
voluntary participation of patients treated by INCIP members.
With a rapidly evolving field like oncology in combination
with a rare and heterogenic population, the need for further
expansion of the INCIP research projects is of the utmost
importance to provide these patients with the best possible
knowledge and reduce adverse outcomes. We therefore invite
all healthcare professionals confronted with pregnant cancer
patients to contact national experts or the INCIP to gain up-to-
date knowledge on their specific situation and, in addition, to
Fig. 2 Multidisciplinary clinical care pathway for patients confronted with a cancer diagnosis during pregnancy
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establish a national advisory board and participate in INCIP
research projects (www.cancerinpregnancy.org).
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